Back to top
more

Sanofi (SNY)

(Real Time Quote from BATS)

$51.51 USD

51.51
602,854

+0.25 (0.49%)

Updated Nov 7, 2024 01:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sanofi (SNY) Stock Moves -0.45%: What You Should Know

by Zacks Equity Research

In the latest trading session, Sanofi (SNY) closed at $55.47, marking a -0.45% move from the previous day.

Zacks.com featured highlights include Unum, Graphic Packaging Holding, AutoNation and Sanofi

by Zacks Equity Research

Unum, Graphic Packaging Holding, AutoNation and Sanofi are part of the Zacks Screen of the Week article.

Will Sanofi (SNY) Surpass Estimates This Earnings Season?

by Zacks Equity Research

Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent.

Zacks.com featured highlights include Unum Group, Sanofi, KB Home, PVH and Telefonica Brasil

by Zacks Equity Research

Unum Group, Sanofi, KB Home, PVH and Telefonica Brasil are part of the Zacks Screen of the Week article.

Vasundhara Sawalka headshot

4 Stocks Trading Near 52-Week High That Can Scale Higher

by Vasundhara Sawalka

Investors target stocks that have been on a bullish run lately. Stocks like UNM, GPK, SNY and AN that are seeing price strength have a high chance of carrying the momentum forward.

Nektar (NKTR) Starts New Restructuring Plan to Curb Cash Burn

by Zacks Equity Research

The new restructuring plan will allow Nektar (NKTR) to extend its cash runway into mid-2026. The company plans to reduce its workforce by approximately 60%.

FDA Expands AbbVie's (ABBV) Qulipta Label in Chronic Migraine

by Zacks Equity Research

Following FDA's label-expansion approval, AbbVie's (ABBV) Qulipta is the first and the only oral CGRP receptor antagonist approved to prevent episodic and chronic migraines.

J&J (JNJ) Q1 Earnings & Sales Top, 2023 View Up, Stock Rises

by Zacks Equity Research

J&J (JNJ) beats estimates for first-quarter earnings and sales. It raises full-year sales and earnings guidance.

Zacks.com featured highlights include Sanofi, Medallion Financial, Plains All American Pipeline and KB Home

by Zacks Equity Research

Sanofi, Medallion Financial, Plains All American Pipeline and KB Home are part of the Zacks Screen of the Week article.

Anindya Barman headshot

Pick These 5 Bargain Stocks With Amazingly Low EV/EBITDA Ratios

by Anindya Barman

We have screened bargain stocks UNM, SNY, KBH, PVH and VIV based on the EV-to-EBITDA ratio, which offers a clearer picture of valuation and earnings potential.

3 Reasons Growth Investors Will Love Sanofi (SNY)

by Zacks Equity Research

Sanofi (SNY) possesses solid growth attributes, which could help it handily outperform the market.

SNY vs. LLY: Which Stock Is the Better Value Option?

by Zacks Equity Research

SNY vs. LLY: Which Stock Is the Better Value Option?

Is Innoviva (INVA) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Will J&J (JNJ) Pharma Unit Outperform Market & Drive Q1 Results?

by Zacks Equity Research

In J&J's (JNJ) Pharma segment, its oncology drug, Darzalex as well as a psoriasis treatment, Stelara is likely to have driven sales growth in the first quarter

Rajani Lohia headshot

4 Low Price-to-Sales Stocks to Get the Best of the Market

by Rajani Lohia

The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like SNY, MFIN, PAA and KBH hold promise.

AstraZeneca (AZN), Sanofi Simply RSV Antibody Agreement Terms

by Zacks Equity Research

AstraZeneca (AZN) and Sanofi (SNY) revise the contractual terms of the agreement for Beyfortus. Sanofi will have full commercial control of Beyfortus in the United States.

Sanofi (SNY) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Sanofi (SNY) closed at $54.18, marking a -0.44% move from the previous day.

Sanofi (SNY) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Sanofi (SNY) closed at $53.22 in the latest trading session, marking a +1.16% move from the prior day.

The Zacks Analyst Blog Highlights Sanofi, Regeneron, AbbVie, Roche and Eli Lilly

by Zacks Equity Research

Sanofi, Regeneron, AbbVie, Roche and Eli Lilly are included in this Analyst Blog.

Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%

by Zacks Equity Research

Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.

Kinjel Shah headshot

Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL

by Kinjel Shah

Sanofi's (SNY) Dupixent succeeds in a pivotal study for COPD. FDA gives CRL to AbbVie's (ABBV) Parkinson's disease therapy, ABBV-951

Sanghamitra Saha headshot

ETFs in Focus on Sanofi and Regeneron's COPD Drug Data

by Sanghamitra Saha

Shares of drugmakers Sanofi and Regeneron surged more than 6% on Mar 23 on COPD drug data.

Sanofi (SNY) Moves 6.0% Higher: Will This Strength Last?

by Zacks Equity Research

Sanofi (SNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Sanofi's (SNY) Dupixent Meets Goal in Pivotal COPD Study

by Zacks Equity Research

Sanofi (SNY) and partner Regeneron's (REGN) Dupixent led to a 30% decline in exacerbations per a late-stage pivotal study on chronic obstructive pulmonary disease.